Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• BofA turns S&P 500 signals from red to yellow: What to buy now
• HawkEye 360 lock-up ends early, shares eligible Sept. 2